Daily Brief Australia: Pioneer Credit, ADX Energy Ltd, Recce Ltd and more

• Pioneer Credit Limited (ASX:PNC) was founded in 2009 and listed on the ASX in 2014.
• The company has grown to be one of the leading acquirers and managers of impaired credit in Australia by; maintaining strong customer engagement, an unblemished compliance record with ASIC, consistently good Net Promoter Score from customers and strong relationships with Australia’s largest bank and non-bank lenders.
• PNC currently purchases debt from 18 different vendor partners with long-term partnership purchasing arrangements in place with Commonwealth Bank of Australia (ASX:CBA). 

• ADX is issuing A$1.5 mm of loan notes with a term of 18 months.
• A$1.0 mm of the loan notes carry an interest rate of 8% per annum with 30 mm options with an exercise price of A$0.01 per share and 30 mm options with an exercise price of A$0.014 per share.
• ADX expects to secure farm-in partners for some of its Upper Austrian drilling projects during the summer.

Recent months have been eventful for Recce Pharmaceuticals, with the company presenting its Q323 operational update and announcing ethics approval in April 2023 to commence Phase I/II clinical trials in healthy volunteers for the intravenous (IV) formulation of its lead broad-spectrum synthetic polymer anti-infective compound, RECCE 327 (R327), using a more rapid infusion rate. The Phase I part of the study will assess faster infusion rates of R327 in c 16 healthy participants across three cohorts, with the first cohort recently having successfully completed a 2,500mg R327 dose. A Phase II efficacy study in patients with uncomplicated or recurrent urinary tract infections (UTIs) is expected to commence in H2 CY23. While several potential value inflection points may arise in the next 12 months, obtaining financing is likely to be a near-term strategic priority given the current cash at hand (A$4.6m at 28 April 2023). We value Recce at A$535.6m, up from A$497.4m previously.